在过去五年里,对卵巢癌免疫疗法趋势的知识映射和可视化:一个图书识别分析
Kowthar Mohamed Shaie1, Lian Sihan1, Wang Yuli1
1Department of Gynecology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Frontiers in immunology
|October 18, 2024
概括
本文献分析揭示了2019-2023年卵巢癌免疫疗法研究的全球趋势. 中国在出版方面处于领先地位,其中"边界免疫学"是关键期刊,并注意到高度引用论文的峰值.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 图书统计学 图书统计学
背景情况:
- 卵巢癌免疫疗法研究在2019年至2023年期间出现了显著的全球活动.
- 了解研究趋势对于推进治疗策略至关重要.
研究的目的:
- 在卵巢癌研究中对免疫治疗趋势进行文献分析.
- 确定该领域的领先国家,机构和期刊.
- 绘制卵巢癌免疫治疗的演变和新兴领域的地图.
主要方法:
- 在Web of Science核心收藏中进行了全面的文献搜索.
- 包括英语文章和关于"免疫治疗趋势"和"卵巢癌"的评论.
- VOSviewer被用于统计分析和全球贡献的可视化.
主要成果:
- 118个国家做出了贡献,其中中国领先 (3,167个贡献),其次是德国 (558) 和意大利 (547).
- "边界免疫学"发表了最多的论文 (546篇),其次是"癌症"和"瘤学的边界".
- 出版趋势每年增加到2022年,高引用论文的峰值从2019-2022年.
结论:
- 图书统计分析绘制了卵巢癌免疫疗法研究的演变.
- 识别的趋势和关键参与者为未来的研究提供了可操作的见解.
- 通过这些发现,治疗策略和患者结果的战略改进得到了支持.
相关概念视频
Tumor Immunotherapy
488
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


